Frecuencia de preenfermedades en el Hospital Nacional
Resumen
Introducción: la Medicina Preventiva enfatiza la detección de preenfermedades como la prediabetes mellitus, prehipertensión arterial, preobesidad y prehiperuricemia con el propósito de intervenir oportunamente en el desarrollo de estas afecciones.
Objetivos: investigar la prevalencia de preenfermedades en pacientes adultos del Servicio de Consultas de Medicina Interna del Hospital Nacional.
Materiales y métodos: estudio observacional descriptivo, de corte transverso, prospectivo, realizado en varones y mujeres, mayores de edad, del Servicio de Consultas de Medicina Interna del Hospital Nacional de noviembre 2012 a noviembre 2013. Fueron medidas variables demográficas, clínicas y laboratoriales.
Resultados: ingresaron al estudio 267 sujetos, siendo 64 varones con edad media 52±18 años y 203 mujeres con edad media 53±20 años (p 0,62). Se detectaron las sgtes. preenfermedades: prediabetes mellitus 31%, prehipertensión arterial sistólica 32%, prehipertensión arterial diastólica 46%, preobesidad 36%, prehipercolesterolemia 36%, prehipertrigliceridemia 15% y prehiperuricemia 60%.
Conclusiones: las preenfermedades más frecuentes fueron la prehiperuricemia y la prehipertensión arterial diastólica.
Citas
Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998 May 12; 97(18): 1837-47.
Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract. 2002 Jan; 55(1): 65-85.
Saudek CD, Herman WH, Sacks DB, Bergenstal RM, Edelman D, Davidson MB. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab. 2008 Jul; 93(7): 2447-53.
Hoerger TJ, Hicks KA, Sorensen SW, Herman WH, Ratner RE, Ackermann RT, Zhang P, Engelgau MM. Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults. Diabetes Care. 2007 Nov; 30(11): 2874-9.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014 Jan; 37 Suppl 1: S81-90.
Hosler AS. Prevalence of self-reported prediabetes among adults participating in a community-based health awareness program, New York State. Prev Chronic Dis. 2009 Apr; 6(2): A48.
Bloomgarden ZT. American College Of Endocrinology pre-diabetes consensus conference: Part one. Diabetes Care. 2008 Oct;3 1(10): 2062-9.
Bloomgarden ZT. American College of Endocrinology pre-diabetes consensus conference: Part two. Diabetes Care. 2008 Nov; 31(11): 2222-9.
Bloomgarden ZT. American College of Endocrinology pre-diabetes consensus conference: Part three. Diabetes Care. 2008 Dec; 31(12): 2404-9.
Cañete F. Primera encuesta nacional de factores de riesgo y enfermedades no transmisibles Paraguay 2011. /Internet/. Asunción: Ministerio de Salud Pública y Bienestar Social, Dirección Vigilancia de Enfermedades No Transmisibles; 2011 /citado 22 nov 2014/. Disponible en: http://www.nutrisys-py.com/descarga/img/-ENT.pdf
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5; 311(5): 507-20.
Marshall T. The rise of the term prehypertension. Ann Intern Med. 2009 Jan 20; 150(2): 145.
Godwin M, Pike A, Kirby A, Jewer C, Murphy L. Prehypertension and hypertension in a primary care practice. Can Fam Physician. 2008 Oct; 54(10): 1418-23.
Nilsson PM. High-normal blood pressure and future risks a new concern for clinicians?. Eur Heart J. 2007 Dec; 28(23): 2832-3.
Albarwani S, Al-Siyabi S, Tanira MO. Prehypertension: Underlying pathology and therapeutic options. World J Cardiol. 2014 Aug 26; 6(8): 728-43.
De Marco M, de Simone G, Roman MJ, Chinali M, Lee ET, Russell M, Howard BV, Devereux RB. Cardiovascular and metabolic predictors of progression of prehypertension into hypertension: the Strong Heart Study. Hypertension. 2009 Nov; 54(5): 974-80.
U.S. Preventive Services Task Force. Screening for obesity in adults: recommendations and rationale. Ann Intern Med. 2003 Dec 2; 139(11): 930-2.
Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ. 2007 Apr 10; 176(8): S1-13.
Organización Mundial de la Salud. Obesidad y sobrepeso. Nota descriptiva /Internet/. 2014 agosto /citado 22 nov 2014/; (311). Disponible en: http://www.who.int/mediacentre/factsheets/fs311/es/
Ford ES, Mokdad AH. Epidemiology of obesity in the Western Hemisphere. J Clin Endocrinol Metab. 2008 Nov; 93(11 Suppl 1): S1-8.
Rodríguez Caro A, González López-Valcárcel B. The economic implications of interventions to prevent obesity. Rev Esp Salud Pública. 2009 Jan-Feb; 83(1): 25-41.
Rohrer JE, Anderson GJ, Furst JW. Obesity and pre-hypertension in family medicine: implications for quality improvement. BMC Health Serv Res. 2007 Dec 21; 7: 212.
National Cholesterol Education Program (NCEP). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, evaluation, and treatment of high blood cholesterol in adults: Adult treatment Panel III. Final report. Circulation. 2002 Dec 17; 106(25): 3143-421.
McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol. 2006 Sep; 22(11): 913-27.
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1; 63(25 Pt B): 2889-934.
Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric acid and the development of metabolic syndrome in women and men. Metabolism. 2008 Jun; 57(6): 845-52.
Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008 Oct 23; 359(17): 1811-21.
Kutzing MK, Firestein BL. Altered uric acid levels and disease states. J Pharmacol Exp Ther. 2008 Jan;324(1):1-7.
Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006 Jun; 37(6): 1503-7.
Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med. 2008 Jul; 75 Suppl 5: S13-6.
Meisinger C, Koenig W, Baumert J, Döring A. Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population: the MONICA/KORA cohort study. Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1186-92.
Ouppatham S, Bancha S, Choovichian P. The relationship of hyperuricemia and blood pressure in the Thai army population. J Postgrad Med. 2008 Oct-Dec;54(4):259-62.
Ioachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum. 2008 Feb;58(2):623-30.
Richette P1, Perez-Ruiz F. Serum uric acid and metabolic risk. Curr Med Res Opin. 2013 Apr;29 Suppl 3:9-15.
Redberg RF, Benjamin EJ, Bittner V, Braun LT, Goff DC Jr, Havas S, et al. AHA/ACCF 2009 performance measures for primary prevention of cardiovascular disease in adults. Circulation. 2009 Sep 29; 120(13): 1296-336.
Ramírez MO, Pino CT, Furiasse LV, Lee AJ, Fowkes FG. Paraguayan National Blood Pressure Study: prevalence of hypertension in the general population. J Hum Hypertens. 1995 Nov; 9(11): 891-7.
Santa Cruz F, Cabrera W, Barreto S, Mayor MM, Báez D. Kidney disease in Paraguay. Kidney Int Suppl. 2005 Aug; (97): S120-5.
Tsai SP, Wen CP, Chan HT, Chiang PH, Tsai MK, Cheng TY. The effects of pre-disease risk factors within metabolic syndrome on all-cause and cardiovascular disease mortality. Diabetes Res Clin Pract. 2008 Oct; 82(1): 148-56.
Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008 May; 39(5): 1647-52.
US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009 Mar 17; 150(6): 396-404.
Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al. Primary prevention of ischemic stroke. Stroke. 2006 Jun;37(6):1583-633.
Zannad F, Dallongeville J, Macfadyen RJ, Ruilope LM, Wilhelmsen L, De Backer G, et al. Prevention of cardiovascular disease guided by total risk estimations--challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy. Eur J Prev Cardiol. 2012 Dec; 19(6): 1454-64.
Pérez-Fernández GA. La arbitrariedad de los puntos de corte. Una reflexión desde la perspectiva de la pre-enfermedad. Arch Cardiol Mex. 2012; 82(3): 260-1.
Chávez-Domínguez RC. Pre-enfermedad y puntos de corte: cuestionados. Arch Cardiol Mex. 2012; 82(3): 262-4
Zhang Y, Lee ET, Devereux RB, Yeh J, Best LG, Fabsitz RR, Howard BV. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: the Strong Heart Study. Hypertension. 2006 Mar; 47(3): 410-4.
World Health Organization, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. /Internet/ Geneva: WHO; 2006 /citado 22 nov 2014/. Disponible en: https://www.idf.org/webdata/docs/WHO_IDF_definition_diagnosis_of_diabetes.pdf
Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012 Jun 16; 379(9833): 2279-90.
Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010 Feb; 62(2): 170-80.
Aranceta J, Perez-Rodrigo C, Serra-Majem L, Ribas L, Quiles-Izquierdo J, Vioque J, et al. Influence of sociodemographic factors in the prevalence of obesity in Spain. The SEEDO'97 Study. Eur J Clin Nutr. 2001 Jun; 55(6): 430-5.
Cullen P, Schulte H, Assmann G. The Münster Heart Study (PROCAM): Total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. Circulation. 1997 Oct 7; 96(7):2128-36.
Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971 Jan; 74(1): 1-12.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16; 285(19): 2486-97.
Karanja NM, Obarzanek E, Lin PH, McCullough ML, Phillips KM, Swain JF, Champagne CM, Hoben KP. Descriptive characteristics of the dietary patterns used in the Dietary Approaches to Stop Hypertension Trial. DASH Collaborative Research Group. J Am Diet Assoc. 1999 Aug; 99(8 Suppl): S19-27.
Sniderman AD, Beaudry JP, Rahal DP. Early recognition of the patient at late high risk: incomplete infarction and vulnerable myocardium. Am J Cardiol. 1983 Oct 1; 52(7): 669-73.
Stamler J, Neaton JD, Cohen JD, Cutler J, Eberly L, Grandits G, Kuller LH, et al. Multiple risk factor intervention trial revisited: a new perspective based on nonfatal and fatal composite endpoints, coronary and cardiovascular, during the trial. J Am Heart Assoc. 2012 Oct; 1(5): e003640.
Zalawadiya SK, Veeranna V, Mallikethi-Reddy S, Bavishi C, Lunagaria A, Kottam A, Afonso L. Uric acid and cardiovascular disease risk reclassification: findings from NHANES III. Eur J Prev Cardiol. 2014 Jan 15; 0(00):1-6
Moreno Azorero R, Páez M, Jiménez J, Figueredo R, Palacios M, Medina U, Melgarejo MV, Kiefer R, Franco L. Factores de riesgo de la enfermedad cardiovascular en Asunción y área metropolitana. Asunción; EDUNA; 1995.
Jimenez JT, Palacios M, Cañete F, Barriocanal LA, Medina U, Figueredo R, et al. Prevalence of diabetes mellitus and associated cardiovascular risk factors in an adult urban population in Paraguay. Diabet Med. 1998 Apr; 15(4): 334-8.
Jiménez MC, Sanabria MC, Mendoza de Arbo L, González de Szwako R. Factores de riesgo cardiovascular en escolares y adolescentes de una comunidad rural de Amambay. Pediatr. (Asunción) 2011; 38(3): 205-12.
Valencia Martín JL, González MJ, Galán I. Methodological issues in the measurement of alcohol consumption: the importance of drinking patterns. Rev Esp Salud Publica. 2014 Aug; 88(4): 433-46.
Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): An effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998 Sep 14; 158(16): 1789-95.
